LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 42

Search options

  1. Book ; Online: Maligne Lymphome

    Dreyling, Martin / Hentrich, Marcus / Heidegger, Simon

    Empfehlungen zur Diagnostik, Therapie und Nachsorge

    (Manual)

    2023  

    Institution Comprehensive Cancer Center München
    Tumorzentrum München
    Author's details Bandherausgeber M. Dreyling, M. Hentrich, S. Heidegger
    Series title Manual
    Keywords Malignes Lymphom
    Subject Bösartige Lymphome ; Lymphosarkom
    Language German
    Size 1 Online-Ressource (xv, 469 Seiten), Illustrationen, Diagramme
    Edition 12. Auflage
    Publisher Zuckschwerdt
    Publishing place München
    Publishing country Germany
    Document type Book ; Online
    Note Open Access
    HBZ-ID HT030058855
    ISBN 978-3-86371-399-7 ; 3-86371-399-0
    Database ZB MED Catalogue: Medicine, Health, Nutrition, Environment, Agriculture

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article: In Vivo immunogenicity screening of tumor-derived extracellular vesicles by flow cytometry of splenic t cells

    Stritzke, Florian / Poeck, Hendrik / Heidegger, Simon

    Journal of visualized experiments. 2021 Sept. 23, , no. 175

    2021  

    Abstract: Immunogenic cell death of tumors, caused by chemotherapy or irradiation, can trigger tumor-specific T cell responses by releasing danger-associated molecular patterns and inducing the production of type I interferon. Immunotherapies, including checkpoint ...

    Abstract Immunogenic cell death of tumors, caused by chemotherapy or irradiation, can trigger tumor-specific T cell responses by releasing danger-associated molecular patterns and inducing the production of type I interferon. Immunotherapies, including checkpoint inhibition, primarily rely on preexisting tumor-specific T cells to unfold a therapeutic effect. Thus, synergistic therapeutic approaches that exploit immunogenic cell death as an intrinsic anti-cancer vaccine may improve their responsiveness. However, the spectrum of immunogenic factors released by cells under therapy-induced stress remains incompletely characterized, especially regarding extracellular vesicles (EVs). EVs, nano-scale membranous particles emitted from virtually all cells, are considered to facilitate intercellular communication and, in cancer, have been shown to mediate cross-priming against tumor antigens. To assess the immunogenic effect of EVs derived from tumors under various conditions, adaptable, scalable, and valid methods are sought-for. Therefore, herein a relatively easy and robust approach is presented to assess EVs' in vivo immunogenicity. The protocol is based on flow cytometry analysis of splenic T cells after in vivo immunization of mice with EVs, isolated by precipitation-based assays from tumor cell cultures under therapy or steady-state conditions. For example, this work shows that oxaliplatin exposure of B16-OVA murine melanoma cells resulted in the release of immunogenic EVs that can mediate the activation of tumor-reactive cytotoxic T cells. Hence, screening of EVs via in vivo immunization and flow cytometry identifies conditions under which immunogenic EVs can emerge. Identifying conditions of immunogenic EV release provides an essential prerequisite to testing EVs' therapeutic efficacy against cancer and exploring the underlying molecular mechanisms to ultimately unveil new insights into EVs' role in cancer immunology.
    Keywords T-lymphocytes ; cell communication ; cell death ; cytotoxicity ; drug therapy ; flow cytometry ; immunization ; immunogenicity ; interferons ; irradiation ; melanoma ; mice ; neoplasm cells ; vaccines
    Language English
    Dates of publication 2021-0923
    Size p. e62811.
    Publishing place Journal of Visualized Experiments
    Document type Article
    ZDB-ID 2259946-0
    ISSN 1940-087X
    ISSN 1940-087X
    DOI 10.3791/62811
    Database NAL-Catalogue (AGRICOLA)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: In Vivo Immunogenicity Screening of Tumor-Derived Extracellular Vesicles by Flow Cytometry of Splenic T Cells.

    Stritzke, Florian / Poeck, Hendrik / Heidegger, Simon

    Journal of visualized experiments : JoVE

    2021  , Issue 175

    Abstract: Immunogenic cell death of tumors, caused by chemotherapy or irradiation, can trigger tumor-specific T cell responses by releasing danger-associated molecular patterns and inducing the production of type I interferon. Immunotherapies, including checkpoint ...

    Abstract Immunogenic cell death of tumors, caused by chemotherapy or irradiation, can trigger tumor-specific T cell responses by releasing danger-associated molecular patterns and inducing the production of type I interferon. Immunotherapies, including checkpoint inhibition, primarily rely on preexisting tumor-specific T cells to unfold a therapeutic effect. Thus, synergistic therapeutic approaches that exploit immunogenic cell death as an intrinsic anti-cancer vaccine may improve their responsiveness. However, the spectrum of immunogenic factors released by cells under therapy-induced stress remains incompletely characterized, especially regarding extracellular vesicles (EVs). EVs, nano-scale membranous particles emitted from virtually all cells, are considered to facilitate intercellular communication and, in cancer, have been shown to mediate cross-priming against tumor antigens. To assess the immunogenic effect of EVs derived from tumors under various conditions, adaptable, scalable, and valid methods are sought-for. Therefore, herein a relatively easy and robust approach is presented to assess EVs' in vivo immunogenicity. The protocol is based on flow cytometry analysis of splenic T cells after in vivo immunization of mice with EVs, isolated by precipitation-based assays from tumor cell cultures under therapy or steady-state conditions. For example, this work shows that oxaliplatin exposure of B16-OVA murine melanoma cells resulted in the release of immunogenic EVs that can mediate the activation of tumor-reactive cytotoxic T cells. Hence, screening of EVs via in vivo immunization and flow cytometry identifies conditions under which immunogenic EVs can emerge. Identifying conditions of immunogenic EV release provides an essential prerequisite to testing EVs' therapeutic efficacy against cancer and exploring the underlying molecular mechanisms to ultimately unveil new insights into EVs' role in cancer immunology.
    MeSH term(s) Animals ; Extracellular Vesicles ; Flow Cytometry ; Mice ; Neoplasms ; Spleen
    Language English
    Publishing date 2021-09-23
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Video-Audio Media
    ZDB-ID 2259946-0
    ISSN 1940-087X ; 1940-087X
    ISSN (online) 1940-087X
    ISSN 1940-087X
    DOI 10.3791/62811
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article: Oncolytic virotherapy with chimeric VSV-NDV synergistically supports RIG-I-dependent checkpoint inhibitor immunotherapy.

    Marek, Janina / Hanesch, Lorenz / Krabbe, Teresa / El Khawanky, Nadia / Heidegger, Simon / Altomonte, Jennifer

    Molecular therapy oncolytics

    2023  Volume 30, Page(s) 117–131

    Abstract: Unraveling the complexities of the tumor microenvironment (TME) and its correlation with responsiveness to immunotherapy has become a main focus in overcoming resistance to such treatments. Targeting tumor-intrinsic retinoic acid-inducible gene-I (RIG-I), ...

    Abstract Unraveling the complexities of the tumor microenvironment (TME) and its correlation with responsiveness to immunotherapy has become a main focus in overcoming resistance to such treatments. Targeting tumor-intrinsic retinoic acid-inducible gene-I (RIG-I), a sensor for viral RNA, was shown to transform the TME from an immunogenically "cold" state to an inflamed, "hot" lesion, which we demonstrated previously to be a crucial mediator of the efficacy of immune checkpoint inhibition with anti-cytotoxic T lymphocyte-associated protein 4 (CTLA-4). In this study, we focus on the chimeric oncolytic virus vesicular stomatitis virus (VSV)-Newcastle disease virus (NDV), comprised of genetic components of VSV and NDV, and we investigate its utility to support tumor-intrinsic RIG-I-dependent therapy with anti-CTLA-4. Overall, we demonstrate that treatment with VSV-NDV efficiently delays tumor growth and significantly prolongs survival in a murine model of malignant melanoma, which was further enhanced in combination with anti-CTLA-4. Although the direct oncolytic and pro-inflammatory effects of VSV-NDV therapy were independent of RIG-I activation, the synergism with anti-CTLA-4 therapy and associated activation of tumor-specific T cells was critically dependent on active RIG-I signaling in tumor cells. This work highlights the therapeutic value of utilizing an immune-stimulatory oncolytic virus to sensitize tumors to immune checkpoint inhibition.
    Language English
    Publishing date 2023-08-05
    Publishing country United States
    Document type Journal Article
    ISSN 2372-7705
    ISSN 2372-7705
    DOI 10.1016/j.omto.2023.08.001
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article: Herrschinger Hämato-Onkologie-Symposium 2020. CAR-T-Zell-Therapie: Klinische Anwendung und aktuelle Entwicklungen. Simon Heidegger und Angela Krackhardt, Klinikum rechts der Isar der TU München. CAR-T-Zelltherapien haben sich bei Patienten mit bestimmten rezidivierten oder refraktären hämatologischen Neoplasien als vielversprechende neue Behandlungsoptionen erwiesen

    Heidegger, Simon / Krackhardt, Angela

    TZM-News : Sonderausgabe

    2020  Volume -, Issue 1, Page(s) 4

    Language German
    Document type Article
    ZDB-ID 2711416-8
    Database Current Contents Medicine

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 5602 -Sonderausg.-: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book ; Online ; Thesis: Prävalenz und Prädiktoren für Upgrading und Upstaging bei Männern mit Low-Risk und Favorable-Intermediate-Risk Prostatakarzinom unter besonderer Berücksichtigung der onkologischen Familienanamnese

    Maier, Nikola Viktoria Verfasser] / [Herkommer, Kathleen [Akademischer Betreuer] / Herkommer, Kathleen [Gutachter] / Heidegger, Simon [Gutachter]

    2023  

    Author's details Nikola Viktoria Maier ; Gutachter: Kathleen Herkommer, Simon Heidegger ; Betreuer: Kathleen Herkommer
    Keywords Medizin, Gesundheit ; Medicine, Health
    Subject code sg610
    Language German
    Publisher Universitätsbibliothek der TU München
    Publishing place München
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article ; Online: Innate Immune Stimulation in Cancer Therapy.

    Düwell, Peter / Heidegger, Simon / Kobold, Sebastian

    Hematology/oncology clinics of North America

    2019  Volume 33, Issue 2, Page(s) 215–231

    Abstract: The innate immune system has evolved as a first line of defense against invading pathogens and acts via classes of germline-encoded receptor systems to respond with proinflammatory cytokines. Innate immune cells, predominantly cells of the myeloid ... ...

    Abstract The innate immune system has evolved as a first line of defense against invading pathogens and acts via classes of germline-encoded receptor systems to respond with proinflammatory cytokines. Innate immune cells, predominantly cells of the myeloid compartment, are capable of providing a potent basis for boosting adaptive immunity in malignant diseases. The authors review their current understanding of the molecular mechanisms whereby innate pattern recognition receptors participate in immunosurveillance of cancer cells. They discuss how innate effector mechanisms are currently being targeted pharmacologically and how improved understanding of the biology of these pathways is leading to novel immunotherapies of cancer.
    MeSH term(s) Adaptive Immunity ; Animals ; Humans ; Immunity, Innate ; Immunotherapy ; Neoplasms/immunology ; Neoplasms/therapy
    Language English
    Publishing date 2019-01-09
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 93115-9
    ISSN 1558-1977 ; 0889-8588
    ISSN (online) 1558-1977
    ISSN 0889-8588
    DOI 10.1016/j.hoc.2018.12.002
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Se 1077: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Tumor cell-intrinsic RIG-I signaling governs synergistic effects of immunogenic cancer therapies and checkpoint inhibitors in mice.

    Poeck, Hendrik / Wintges, Alexander / Dahl, Sarah / Bassermann, Florian / Haas, Tobias / Heidegger, Simon

    European journal of immunology

    2021  Volume 51, Issue 6, Page(s) 1531–1534

    Abstract: Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small ...

    Abstract Immunogenic cancer therapies, including radiation and hypomethylating agents, such as 5-azacytidine, rely on tumor cell-intrinsic activation of the RNA receptor RIG-I for their synergism with immune checkpoint inhibitors. Possible RIG-I ligands are small nuclear RNA (snRNA) and endogenous retroviral elements (ERV) leaking from the nucleus during programmed cell death.
    MeSH term(s) Animals ; Azacitidine/therapeutic use ; Chemoradiotherapy ; Disease Models, Animal ; Drug Synergism ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy/methods ; Melanoma/immunology ; Melanoma/therapy ; Melanoma, Experimental ; Mice ; Mice, Inbred C57BL ; Receptors, Cell Surface/genetics ; Receptors, Cell Surface/metabolism ; Signal Transduction ; Treatment Outcome
    Chemical Substances Immune Checkpoint Inhibitors ; Receptors, Cell Surface ; Robo3 protein, mouse ; Azacitidine (M801H13NRU)
    Language English
    Publishing date 2021-04-05
    Publishing country Germany
    Document type Letter ; Research Support, Non-U.S. Gov't
    ZDB-ID 120108-6
    ISSN 1521-4141 ; 0014-2980
    ISSN (online) 1521-4141
    ISSN 0014-2980
    DOI 10.1002/eji.202049158
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 489: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MG 85: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Plattenepithelkarzinom des Kopf-Hals-Bereichs: Palliative Systemtherapie

    Schneidawind, Dominik / Frauenfeld, Leonie / Reinert, Christian Philipp / Lengerke, Claudia / Heidegger, Simon

    TumorDiagnostik & Therapie

    2022  Volume 43, Issue 10, Page(s) 671–675

    Keywords Oropharynxkarzinom ; Hypopharynxkarzinom ; Larynxkarzinom ; Metastasen ; Immuntherapie ; zielgerichtete Therapie ; Zytostatika ; monoklonale Antikörper
    Language German
    Publishing date 2022-11-25
    Publisher Georg Thieme Verlag KG
    Publishing place Stuttgart ; New York
    Document type Article
    ZDB-ID 2072365-9
    ISSN 1439-1279 ; 0722-219X
    ISSN (online) 1439-1279
    ISSN 0722-219X
    DOI 10.1055/a-1915-3411
    Database Thieme publisher's database

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: CXCR4-targeted Theranostics in Hematooncology: Opportunities and Challenges.

    Werner, Rudolf / Haug, Alexander / Buske, Christian / Heidegger, Simon / Illert, Anna L / Bassermann, Florian / Herhaus, Peter / Buck, Andreas / Duell, Johannes / Topp, Max S / Kraus, Sabrina / Einsele, Hermann / Lapa, Constantin / Raderer, Markus / Lenz, Georg / Habringer, Stefan / von Tresckow, Bastian / Keller, Ulrich

    Nuklearmedizin. Nuclear medicine

    2024  Volume 63, Issue 2, Page(s) 57–61

    Abstract: C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, ... ...

    Title translation CXCR4-gerichtete Theranostics in der Hämato-Onkologie: Möglichkeiten und Herausforderungen.
    Abstract C-X-C motif chemokine receptor 4 (CXCR4) is overexpressed in a multitude of cancers, including neoplasms of hematopoietic origin. This feature can be leveraged by a theranostic approach, which provides a read-out of the actual CXCR4 expression in vivo, followed by CXCR4-targeted radioligand therapy (RLT) exerting anti-cancer as well as myeloablative efficacy. In a recent meeting of hematooncology and nuclear medicine specialists, statements on the current clinical practice and future perspectives of this innovative concept were proposed and summarized in this opinion article. Experts concluded that i) CXCR4-directed [68Ga]Ga-PentixaFor PET/CT has the potential to improve imaging for patients with marginal zone lymphoma; ii) CXCR4-targeted RLT exerts anti-lymphoma efficacy and myeloablative effects in patients with advanced, treatment-refractory T-cell lymphomas; iii) prospective trials with CXCR4-based imaging and theranostics are warranted.
    MeSH term(s) Humans ; Positron Emission Tomography Computed Tomography/methods ; Precision Medicine ; Prospective Studies ; Neoplasms ; Receptors, CXCR4
    Chemical Substances CXCR4 protein, human ; Receptors, CXCR4
    Language English
    Publishing date 2024-01-08
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2030804-8
    ISSN 2567-6407 ; 0029-5566
    ISSN (online) 2567-6407
    ISSN 0029-5566
    DOI 10.1055/a-2194-9965
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top